Quality of life with quetiapine for schizophrenia or bipolar disorder
Treatments studied
Part of Mental health clinical trials.
This study looks at how well patients feel and how safe it is when taking quetiapine alone or with other medicines for schizophrenia or bipolar disorder. It aims to help doctors understand the best ways to use this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 64 years old
- Have a diagnosis of schizophrenia or bipolar disorder
- Be prescribed quetiapine, either alone or combined with aripiprazole or haloperidol
- Not be pregnant, breastfeeding, or planning to become pregnant soon
- Not have a known allergy or bad reaction to quetiapine or its ingredients
- Not be taking certain other medications (like some HIV treatments, antifungal drugs, or specific antibiotics)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether BXCL501 is safe and can help reduce agitation in children and teens who have bipolar disorder or schizophrenia. You may be considered if your agitation is significant during screening, but certain recent medication and health factors can make you ineligible.
This is an observational (non-intervention) study that follows adults with schizophrenia who are taking specific “atypical” antipsychotic medicines long-term. Researchers want to learn about patients’ experiences and outcomes while on these treatments.
This trial tests whether clozapine works better for people whose illness fits a specific “biotype-1” pattern. It may help reduce ongoing symptoms, but it also requires close safety monitoring.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This trial tests an investigational medication called VV119 for adults experiencing a sudden worsening of schizophrenia symptoms. It aims to see if the drug is safe and effective in reducing symptoms like delusions, hallucinations, and disorganized thinking.
This trial studies a type of talk therapy (IPSRT) for people with bipolar II disorder who are currently depressed. The aim is to see how well it works and how it affects the brain.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.